ARGX ARGENX SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY89.9%
TTM net income YoY55.1%
TTM EPS YoY53.1%
Revenue 3-yr CAGR118.0%
Net income 3-yr CAGR—
Margins
Gross margin89.1%
Operating margin25.4%
Net margin31.1%
FCF margin16.4%
EBITDA margin—
Returns
ROE20.2%
ROA17.4%
ROIC (approx.)26.9%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets15.7%
Debt / equity0.00x
Current ratio5.23x
Interest coverage258.16x
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio8.2%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.15B | $2.19B | $1.19B | $400.72M | $497.28M |
| Cost of revenue | $450.67M | $227.29M | $117.83M | $29.43M | — |
| Gross profit | $3.70B | $1.96B | $1.07B | $371.29M | — |
| R&D expense | $1.36B | $983.42M | $859.49M | $663.37M | $580.52M |
| SG&A expense | $1.37B | $1.06B | $711.90M | $472.13M | $307.64M |
| Operating income | $1.05B | -$21.65M | -$425.05M | -$720.34M | -$348.75M |
| Interest expense | $4.08M | $2.46M | $906,000 | $3.91M | $4.58M |
| Pretax income | $1.28B | $85.18M | -$304.50M | -$729.31M | -$399.74M |
| Income tax | -$13.43M | -$747.86M | -$9.44M | -$19.72M | $8.52M |
| Net income | $1.29B | $833.04M | -$295.05M | -$709.59M | -$408.26M |
| EPS (basic) | 21.08 | 13.92 | -5.16 | -13.05 | -7.99 |
| EPS (diluted) | 19.57 | 12.78 | -5.16 | -13.05 | -7.99 |
| Weighted avg. shares (diluted) | 66.03M | 65.18M | 57.17M | 54.38M | — |
| Balance sheet | |||||
| Cash & equivalents | $3.49B | $1.50B | $2.05B | $800.74M | $1.33B |
| Receivables | $1.65B | $904.47M | $496.69M | $275.70M | $38.22M |
| Inventory | $473.53M | $407.23M | $310.55M | $228.35M | $109.08M |
| Current assets | $6.90B | $4.88B | $4.12B | $2.77B | $2.54B |
| PP&E, netmay include right-of-use assets (IFRS) | $48.25M | $43.52M | $22.68M | $16.23M | $15.84M |
| Intangibles | $272.10M | $181.44M | $125.23M | $174.90M | $171.68M |
| Total assets | $8.68B | $6.20B | $4.54B | $3.13B | $2.85B |
| Current liabilities | $1.32B | $669.92M | $422.99M | $302.28M | $301.24M |
| Total liabilities | $1.36B | $704.24M | $444.95M | $320.56M | $316.05M |
| Shareholders' equity | $7.32B | $5.50B | $4.10B | $2.81B | $2.53B |
| Shares outstanding | 61.88M | 60.76M | 59.19M | 55.40M | 51.67M |
| Cash flow statement | |||||
| Operating cash flow | $685.19M | -$82.75M | -$420.33M | -$862.81M | -$606.81M |
| Capital expenditure | $6.17M | $1.80M | $812,000 | $837,000 | $3.62M |
| Free cash flow | $679.03M | -$84.55M | -$421.14M | -$863.64M | -$610.43M |
| Investing cash flow | $984.00M | -$717.59M | $308.21M | -$461.18M | -$347.07M |
| Financing cash flow | $233.01M | $279.76M | $1.34B | $843.76M | $1.12B |
| Stock-based compensation | $248.08M | $235.18M | $232.97M | $157.03M | $179.37M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.